Janus Henderson Group PLC Has $66.35 Million Position in Bicara Therapeutics Inc. $BCAX

Janus Henderson Group PLC grew its position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) by 26.2% during the first quarter, HoldingsChannel.com reports. The firm owned 3,339,218 shares of the company’s stock after purchasing an additional 692,933 shares during the period. Janus Henderson Group PLC owned approximately 0.05% of Bicara Therapeutics worth $66,350,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of BCAX. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Bicara Therapeutics in the fourth quarter worth $45,000. Legal & General Group Plc raised its position in Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after purchasing an additional 1,233 shares during the last quarter. Larson Financial Group LLC raised its position in Bicara Therapeutics by 1,015.5% during the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after purchasing an additional 3,595 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after buying an additional 3,866 shares during the period. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in Bicara Therapeutics by 385.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock worth $97,000 after buying an additional 4,585 shares during the period.

Bicara Therapeutics Stock Up 3.2%

BCAX stock opened at $27.10 on Friday. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of -9.75 and a beta of -0.81. The company’s fifty day simple moving average is $25.19 and its 200 day simple moving average is $21.20. Bicara Therapeutics Inc. has a 12-month low of $9.57 and a 12-month high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). Research analysts expect that Bicara Therapeutics Inc. will post -3.42 earnings per share for the current year.

Insider Buying and Selling at Bicara Therapeutics

In other news, CFO Ivan Hyep sold 28,000 shares of the stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $28.85, for a total transaction of $807,800.00. Following the transaction, the chief financial officer owned 129,855 shares of the company’s stock, valued at $3,746,316.75. This represents a 17.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ryan Cohlhepp sold 28,214 shares of the company’s stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $28.98, for a total value of $817,641.72. Following the transaction, the chief operating officer directly owned 182,177 shares in the company, valued at approximately $5,279,489.46. This trade represents a 13.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 88,450 shares of company stock valued at $2,366,675. 13.80% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on BCAX shares. The Goldman Sachs Group upped their price target on Bicara Therapeutics from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Tuesday, May 12th. Guggenheim initiated coverage on Bicara Therapeutics in a research note on Monday, May 11th. They issued a “buy” rating and a $42.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Bicara Therapeutics in a report on Wednesday, May 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Monday, July 6th. Finally, Wall Street Zen upgraded shares of Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, May 24th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $30.27.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.